Skip to main content Accessibility help
×
Hostname: page-component-84b7d79bbc-dwq4g Total loading time: 0 Render date: 2024-07-28T11:17:26.693Z Has data issue: false hasContentIssue false

145 - Venlafaxine

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Effexor, Effexor XR, Effexor XL, Efectin, Efexor, Trevilor, Venla

Generic?

• Yes

Class

• Serotonin and norepinephrine reuptake inhibitor (SNRI)

Commonly Prescribed for

(FDA approved in bold)

Major depressive disorder

Generalized anxiety disorder (Effexor XR only)

Panic disorder (Effexor XR only)

Social phobia (Effexor XR only)

• Migraine or tension-type headache prophylaxis

• Diabetic neuropathy

• Other painful peripheral neuropathies

• Cancer pain (neuropathic)

• Depression secondary to stroke

• Stress urinary incontinence

• Fibromyalgia

• Binge-eating disorder

• Post-traumatic stress disorder (PTSD)

• Attention deficit hyperactivity disorder

• Perimenopausal/menopausal hot flushes

• Cataplexy

How the Drug Works

• Both venlafaxine and its active metabolite (desvenlafaxine) are potent inhibitors of serotonin and norepinephrine reuptake transporters (SERT, NET), increasing serotonin and norepinephrine levels within hours, but antidepressant effects take weeks. Effect is more likely related to adaptive changes in serotonin and norepinephrine receptor systems over time

• Weakly blocks dopamine reuptake pump (dopamine transporter)

• Interacts with μ-opioid receptors and α2-adrenergic receptor

How Long Until It Works

• Migraines: effective in as little as 2 weeks, but can take up to 10 weeks on a stable dose to see full effect

• Tension-type headache prophylaxis: effective in 4–8 weeks

• Neuropathic pain: usually some effect within 4 weeks

• Diabetic neuropathy: may have significant improvement with high doses within 6 weeks

• Depression: 2 weeks but up to 2 months for full effect

If It Works

• Migraine/tension-type headache: goal is a 50% or greater reduction in headache frequency or severity. Consider tapering or stopping if headaches remit for more than 6 months or if considering pregnancy

• Neuropathic pain: the goal is to reduce pain intensity and symptoms, but usually does not produce remission. Continue to use and monitor for AEs

• Diabetic neuropathy: the goal is to reduce pain intensity and reduce use of analgesics, but usually does not produce remission. Continue to use and maintain strict glycemic control and diabetic management

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 534 - 538
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Venlafaxine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.146
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Venlafaxine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.146
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Venlafaxine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.146
Available formats
×